高 永達

Medicine & Life Sciences

1. Endothelial Progenitor Cells 100%
2. Taiwan 90%
3. Myocardial Infarction 85%
4. Dipeptidyl-Peptidase IV Inhibitors 71%
5. Rivaroxaban 71%
6. Coronary Vessels 66%
7. Osteoporotic Fractures 64%
8. Cohort Studies 60%
9. MK0626 58%
10. Renin-Angiotensin System 56%
11. Population 52%
12. Atrial Fibrillation 48%
13. Computed Tomography Angiography 45%
14. Subacute Bacterial Endocarditis 44%
15. Angiography 43%
16. caffeic acid phenethyl ester 42%
17. Stents 40%
18. Angiotensin Receptor Antagonists 40%
19. Sitagliptin Phosphate 38%
20. Abciximab 38%
21. ST Elevation Myocardial Infarction 38%
22. Circulating MicroRNA 37%
23. N,N-dimethylarginine 37%
24. Calcium 37%
25. Tomography 37%
26. Atherosclerotic Plaques 36%
27. Coronary Angiography 35%
28. Survival 35%
29. 3-hydroxy-3-methylglutaryl-coenzyme A 35%
30. Angiotensin-Converting Enzyme Inhibitors 35%
31. Nitric Oxide Synthase 35%
32. Haptoglobins 34%
33. Ischemia 32%
34. Angiogenesis Inhibitors 32%
35. AMP-Activated Protein Kinases 32%
36. Extracorporeal Membrane Oxygenation 32%
37. Cardiogenic Shock 31%
38. Vascular Stiffness 31%
39. Safety 31%
40. Hydroxymethylglutaryl-CoA Reductase Inhibitors 30%
41. Percutaneous Coronary Intervention 30%
42. Venous Thromboembolism 29%
43. Warfarin 28%
44. Biomarkers 27%
45. Angioplasty 27%
46. Pulmonary Embolism 26%
47. Cardiology 26%
48. Autophagy 26%
49. Mortality 25%
50. Glioma 25%